Trial Profile
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 06 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Nov 2013 Planned end date changed from 1 Apr 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 10 May 2012 Trial phase changed from III to I as reported by ClinicalTrials.gov.